文献速递血液净化与透析

牛磺罗定/尿激酶与牛磺罗定/肝素作为血液透析隧道导管封管液的疗效与安全性:前瞻性随机对照研究

Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本研究为前瞻性随机对照试验,比较牛磺罗定/肝素(Taurolock/Hep)与牛磺罗定/尿激酶(Taurolock/U)作为血液透析隧道导管封管液的效果。共纳入Taurolock/Hep组93例次(85例患者)和Taurolock/U组84例次(79例患者),随访6个月。结果显示Taurolock/U组全因导管更换(急性血栓和CRBSI)显著更低(P=0.028),rt-PA使用显著更少(P=0.006),且血流量和Kt/V更高但差异不完全显著。结论认为Taurolock/U是安全有效的封管液,导管更换率低。

要点

  • Taurolock/U组全因导管更换(急性血栓和CRBSI)显著低于Taurolock/Hep组(P=0.028)。
  • Taurolock/U组rt-PA使用显著少于Taurolock/Hep组(P=0.006)。
  • Taurolock/U组血流量和Kt/V更高,但差异不完全显著。

核心结论

  • Taurolock/U是安全有效的隧道透析导管封管液,导管更换率低。

研究设计与样本

  • 前瞻性随机对照试验,Taurolock/Hep组93例次(85例患者),Taurolock/U组84例次(79例患者),随访6个月。

主要发现

  • Taurolock/Hep组因急性血栓移除3根导管,Taurolock/U组无因急性血栓移除导管。
  • 全因导管更换(急性血栓和CRBSI)总数Taurolock/U组显著更低(P=0.028)。
  • rt-PA使用Taurolock/U组显著少于Taurolock/Hep组(P=0.006)。
  • Taurolock/U组血流量和Kt/V高于Taurolock/Hep组,但差异不完全显著。

临床怎么用

  • 对于血液透析隧道导管患者,可考虑使用Taurolock/U作为封管液以减少导管更换和rt-PA使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Taurolidine citrate with heparin (Taurolock/Hep) is a promising central venous catheter lock solution. Despite its universal use among our hemodialysis patients, the prevalence of catheter malfunction was high. We aimed to compare Taurolock/Hep and taurolidine citrate with urokinase (Taurolock/U) as a catheter lock solution in order to identify whether either solution could reduce catheter-related dysfunction. METHODS: In this prospective, randomized, controlled trial, patients were randomized to receive either Taurolock/Hep or Taurolock/U and were followed for 6 months. Episodes of acute catheter thrombosis, requirement of recombinant tissue plasminogen activator (rt-PA) and incidence of catheter-related blood stream infection (CRBSI) were recorded, along with dialysis adequacy (Kt/V), blood flow rates (BFRs) and adverse events. RESULTS: There were 93 inclusions (85 patients) in the Taurolock/Hep group and 84 inclusions in the Taurolock/U group (79 patients). Three catheters were removed in the Taurolock/Hep group because of acute thrombosis, while no catheter was removed for the same reason in the Taurolock/U group. The total number of all-causes catheter exchange (acute thrombosis and CRBSI) was significantly lower in Taurolock/U group (P = 0.028). rt-PA was used significantly less often in the Taurolock/U group than in the Taurolock/Hep group (P = 0.006). Moreover, higher BFR and Kt/V were noted in the Taurolock/U group than in the Taurolock/Hep group, although the differences were not uniformly significant. CONCLUSION: Taurolock/U is a safe and effective tunneled dialysis catheter lock solution, with a low rate of catheter exchange.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Al-Ali F, Hamdy AF, Hamad A, et al. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study. Nephrol Dial Transplant. 2018. PMID: 29106676. doi:10.1093/ndt/gfx187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。